Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, prima dell'apertura del mercato. L'azienda terr脿 una webcast alle 8:00 a.m. ET per discutere i risultati e fornire aggiornamenti sul business.
Esperion 猫 una societ脿 biofarmaceutica commerciale che sviluppa farmaci orali approvati dalla FDA, da assumere una volta al giorno e non appartenenti alla classe delle statine, destinati a pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dal trial CLEAR Cardiovascular Outcomes con 14.000 pazienti. L'azienda sta inoltre portando avanti un programma di nuova generazione focalizzato sullo sviluppo di inibitori della ATP citrato liasi (ACLYi).
Esperion (NASDAQ: ESPR) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, antes de la apertura del mercado. La compa帽铆a realizar谩 una transmisi贸n en vivo a las 8:00 a.m. ET para discutir los resultados y proporcionar actualizaciones comerciales.
Esperion es una empresa biofarmac茅utica en etapa comercial que desarrolla medicamentos orales aprobados por la FDA, de administraci贸n diaria y no estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos cuentan con el respaldo del ensayo CLEAR Cardiovascular Outcomes con 14,000 pacientes. La empresa tambi茅n est谩 avanzando en su programa de pr贸xima generaci贸n centrado en el desarrollo de inhibidores de la ATP citrato liasa (ACLYi).
Esperion (NASDAQ: ESPR)鞚� 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 5鞚� 鞛� 鞁滌瀾 鞝勳溂搿� 鞓堨爼頄堨姷雼堧嫟. 須岇偓電� 霃欕秬 響滌鞁� 鞓れ爠 8鞁�鞐� 鞗轨簮鞀ろ姼毳� 臧滌禍頃橃棳 鞁れ爜鞚� 雲检潣頃橁碃 牍勳雼堨姢 鞐呺嵃鞚错姼毳� 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
Esperion鞚� 靸侅梾 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, FDA 鞀轨澑鞚� 氚涭潃 頃橂（ 頃� 氩� 氤奠毄頃橂姅 瓴疥惮鞖� 牍勳姢韮�韹搓硠 鞁槇甏� 歆堩櫂 頇橃瀽鞖� 鞎诫鞚� 臧滊皽頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞎诫霌れ潃 14,000氇� 頇橃瀽毳� 雽�靸侅溂搿� 頃� CLEAR 鞁槇甏� 瓴瓣臣 鞁滍棙鞙茧 霋冯皼旃惄雼堧嫟. 須岇偓電� 霕愴暅 ATP 鞁滍姼毳挫偘 攵勴暣須唽 鞏奠牅鞝�(ACLYi) 臧滊皽鞐� 欷戩爯鞚� 霊� 彀劯雽� 頂勲攴鸽灗鞚� 歆勴枆 欷戩瀰雼堧嫟.
Esperion (NASDAQ : ESPR) a programm茅 l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le 5 ao没t 2025, avant l'ouverture des march茅s. La soci茅t茅 organisera un webcast 脿 8h00 ET pour discuter des r茅sultats et fournir des mises 脿 jour commerciales.
Esperion est une soci茅t茅 biopharmaceutique en phase commerciale d茅veloppant des m茅dicaments oraux, une fois par jour, non-statines, approuv茅s par la FDA, destin茅s aux patients atteints de maladies cardiovasculaires avec un LDL-C 茅lev茅. Leurs m茅dicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes de 14 000 patients. La soci茅t茅 fait 茅galement progresser son programme de nouvelle g茅n茅ration ax茅 sur le d茅veloppement d'inhibiteurs de l'ATP citrate lyase (ACLYi).
Esperion (NASDAQ: ESPR) hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 5. August 2025 vor B枚rsenbeginn geplant. Das Unternehmen wird um 8:00 Uhr ET ein Webcast veranstalten, um die Ergebnisse zu besprechen und gesch盲ftliche Updates zu geben.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene, orale, einmal t盲glich einzunehmende Nicht-Statin-Medikamente f眉r Patienten mit Herz-Kreislauf-Erkrankungen und erh枚htem LDL-C entwickelt. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Studie mit 14.000 Patienten unterst眉tzt. Das Unternehmen arbeitet zudem an einem Next-Generation-Programm zur Entwicklung von ATP-Citrat-Lyase-Inhibitoren (ACLYi).
- None.
- None.
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on and .
Esperion Contact Information:
Investors:
Alina Venezia
(734) 887-3903
Media:
Tiffany Aldrich
(616) 443-8438
FAQ
When will Esperion (ESPR) report Q2 2025 earnings?
What time is Esperion's Q2 2025 earnings call?
How can I access Esperion's Q2 2025 earnings webcast?
What are Esperion's main products and focus areas?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
